Table 1:
Condition | Prevalence | Incidence | Annual Direct Costs (2019 Values in Parentheses) | Annual Indirect Cost (2019 Values in Parentheses) | Annual Total Cost (2019 Values in Parentheses) | Activity Limitations | Work Limitations |
---|---|---|---|---|---|---|---|
Amputation | - 1.6 million (Ziegler-Graham et al17**; Ma et al5) |
General Population - 3.0 per 10,000 non-traumatic LEA (Gregg etal18**; Narres et al19) Diabetes-related - 46.2 per 10,000 LEA (Geiss et al20**) - 28.4 per 10,000 LEA (Gregg et al18**; Narres et al19) - 23 per 10,000 LEA above ankle, adults ≥65 (Newhall et al107) - 45 per 10,000 LEA Medicare population (Margolis et al108) |
- $509,275 ($878,927) total projected lifetime healthcare costs after LEA (MacKenzie et al21; Ma et al5) - $14,088 ($20,207) mean cost of LEA procedure due to peripheral vascular disease; $22,405 ($32,136) total inpatient cost year prior to amputation + amputation, adults ≥66 (Goodney et al22) - $17,103 ($24,010) mean cost per inpatient stay for diabetes-related LEA (Yin et al23) |
No new information identified. | Wo new information identified. | - 53.9% non-ambulatory at approximately 1 yr after major LEA (Chopra et al24) - 42.2% and 28.6% of military individuals with traumatic transfemoral and through-knee amputation, respectively, reported being fully disabled and unable to return to duty (Tennent et al25) |
- 42% report being unable to work 7 years after traumatic LEA; of those who could work, 20–25% reported work limitations (MacKenzie et al;26 Ma et al5) |
Back Pain | - 28.6% LBP among community-dwelling adults aged 18–85 (Yang and Haldeman44**) - 25.7% LBP among employed adults (Yang et al45**) - 13.1% cLBP adults aged 20–69 (Shmagel et al43**) - 33.9% back pain among community-dwelling adults (BMUS 4th ed.30†) - 15.0% neck pain among community-dwelling adults (BMUS 4th ed.30†) - 12.9% prevalence of LBP among all ages; peak prevalence is 25.6% adults aged 80–84 (IHMEGBDTool 201732†) |
- 67% of men and 61 % of women aged ≥65 (Marshall et al, 201749; Marshall et al, 201650) - 12–14% of all adults have back pain annually; 57.1 million annual patient visits related to back pain, giving a rate of 18.1 persons in 100 seeking care (BMUS 4th ed30†) - 5,213 per 100,000 incidence of LBP among all ages; peak incidence is 10,425 per 100,000 among adults aged 75–79 (IHMEGBD Tool 201732†) |
- $315 ($365) billion annual all-cause medical costs from 2012–2014; $9,035 all-cause per patient direct costs; $1,615 ($1,873) per patient incremental costs (BMUS 4th ed.30†) - $56.5 ($62.3) billion national spine condition-related costs (AHRQ46†) - $6,892 ($10,104) LBP vs $2,091 ($3,066) for employee matched controls ages 18–64 (Ivanovaet al47**; Tymecka-Woszczerowicz et al48) - $8,296 ($11,231) uncomplicated LBP medical cost per case for working adults ≥18 (Shraim et al109) |
- $2,606 ($3,289) LBP-related cost per employed patient (private health insurance) (Ivanova et al47**; Tymecka-Woszczerowicz et al48) | - $9,498 ($11,986) LBP-related cost per employed patient on private health insurance (Ivanova, et al47**; Tymecka-Woszczerowicz et al48) | - 30% of men and 22% of women ≥65 reported limited activity (Marshall et al, 201749; Marshall et al, 2016;50) - 3,180,600 years lived with disability from LBP (Murray et al52) - 347% greater likelihood of difficulty performing ADLS among adults ≥70 with restricting back pain vs matched controls (Markis et al51) |
- 98 days mean length of disability among adults in 12 months after uncomplicated LBP diagnosis (Shraim et al109) - 12.8% of those with cLBP received disability; those with cLBP were less likely to work (Shmagel et al43) - 8.4 days of medically-related absenteeism on average for working adults (Ivanova et al47) - 25.8% (4.9 million) of adults reporting a health condition that precludes work are unable/limited in work due to chronic back or neck problems (BMUS 4th ed.30†) - Almost 264 million work days lost in one year related to back pain (BMUS 4th ed.30†) - 385,000 self-reported lost work days due to back pain (BMUS 4th ed.30†) |
Multiple Sclerosis | - 727,344 (Wallin et al53**) - 150 per 100,000 (Dilokthornsakul et al;54) - 0.13% prevalence among all ages; peak prevalence is 0.21 % among adults aged 50–54 (IHME GBD Tool 201732†) |
- 3 per 100,000 incidence among all ages; 11.7 per 100,000 peak incidence in adults 25–29 (IHME GBD Tool 201732†) | - $4.3 ($5.0) billion national inpatient charges w/o professional fees (Chen et al110) - $4.0 ($4.4) billion Medicare Part D expenditure for MS-drugs (Hartung et al111) - $51,825-$67,116 ($57,172-$74,041 Jail-cause cost per pt depending on severity of disability (Jones et al55*) - $26,520 ($32,655) MS-related costs per pt on average vs $39,948 ($49,189) per pt with malaise/fatigue (Carroll et al112) - $17,545–41,969 ($21,604–51,678) all-cause, first yr since dx; $8,803–29,355 ($10,839–36,146) MS-related, first yr since dx (Parisé et al56*) |
- $4,146–9,226 ($4,690–10,437) all-cause; $1613–6939 ($1,825–7850) MS-related (Parise et al56) | - $53,438–74,055 ($58,997–81,890) per patient (aggregating Parisé et al56 and Jones et al55) | - 51.2% of working age adults reported using a mobility device; 68.2% reported having some level of mobility limitation (Bishop et al57) - 14.1% and 7.5% of patients on DMDs report malaise/fatigue and gait abnormality, respectively (Carroll et al112) |
- 40.7–48.1% employment post-diagnosis (full- or part-time), compared to 88.2% at time of diagnosis (Bishop et al57; Krause et al, 2019;59 Krause et al, 201858) |
Osteoarthritis | - 13.4% (30.8 million) (Cisternas et al33**) - 15.1 million adults ≥25 with symptomatic knee OA (Deshpande et al35**) - 19.6% age-standardized prevalence of radiographic hip OA; 4.2% age-standardized prevalence of symptomatic hip OA (Kim et al113) - 10.5% all-ages (IHME GBD Tool 201732t) - 32.5 million adults from 2008–2014 (BMUS 4th ed.30†) - 10.5% prevalence among all ages; peak prevalence is 47.8% aged 90–94 (IHME GBD Tool 201732†) |
- 13.8% lifetime risk of diagnosed symptomatic knee OA (Losina et al36**) - 12.9% symptomatic hand OA over 12 years (Snyder et al114) - 1,300 per 100,000 for symptomatic hip OA(Moss et al115) - 460 per 100,000 among all ages; peak incidence is 1,216 per 100,000 among adults aged 60–64 (IHME GBD Tool 201732†) |
- $373.2 ($459.5) billion national all-cause; $65.5 billion ($80.6) OA-related; $11,502 ($14,163) per pt all-cause; $2,018 OA-related (BMUS 4th ed.30†) - $16.5 ($19.2) billion in national inpatient spending (Torio et al116) - $14,521 ($15,435) per pt all-cause general OA in a working-age population; $10,892 ($11,578) incremental; $23,272 ($24,737) all-cause hipOA; $19,551 ($20,782) all-cause spine OA; $15,599 ($16,581) all-cause knee OA; and $10,112 ($10,749) all-cause hand OA (Wang et al34**) - $19,600 ($22,726) knee OA-related lifetime cost (Losina et al37**) - $1,229 ($1274) per pt knee OA-related (Ong et al117) |
- $113.2 ($128.0) billion all-cause earnings lost; $71.3 ($80.7) billion OA-related earnings lost; $6,783 ($7,673) per pt earnings lost; $4,274 ($4,835) OA-related per pt earnings lost (BMUS 4th ed.30†) | - $486.4 ($550.2) billion total direct and indirect costs of OA and allied disorders; $136.8 ($154.8) billion total OA-related costs (BMUS 4th ed.30†) | - 43.5% of individuals with arthritis (23.7 million) had arthritis-attributable activity limitations, the majority of which are likely attributed to osteoarthritis) (Barbour et al27) | - 180.9 million total lost work days reported by adults with arthritis between 2013–2015; the majority likely attributed to osteoarthritis (BMUS 4th ed.30†) |
Rheumatoid Arthritis | - 0.5% (1.3–1.4 million adults) (Hunter et al38**) - 0.8% (1.7 million adults on average from 2008–2012) (BMUS 4th ed.30†) - 2.0% among Medicare beneficiaries (Li et al118) - 0.63% (Crane et al119) - 0.6% prevalence among all ages’ peak prevalence is 1.7% among adults aged 70–74 (IHME GBD Tool32†) |
- 71 per 100,000 age- and sex-adjusted rate for persons at risk (Crane etal119) - 30.2 per 100,000 incidence among all ages; 77 per 100,000 peak incidence among adults aged 65–69 (IHME GBD Tool 201732†) |
- $32.9 ($40.5) billion national all-cause; $13.8 ($17.0) billion RA-related (BMUS 4th ed.30†) - $20,919 ($24,255) all-cause RA in Medicare population;$13,722 ($15,911) incremental; $11,587 ($13,435) RA-related (Chen I Chieh et al39**) - $12,509 ($13,800) per pt all-cause; $3,723 ($4,107) per pt RA-related costs (Hresko et al14*) - $14,158 ($14,682) per pt RA-related (Li et al120) - $5,317 ($6,020) RA-related costs for pts on targeted immunomodulators (Strand et al42) |
- $13.1 ($14.8) billion national earning loss and $14,542 ($16,450) per pt earning losses; RA-related earning losses were $7.9 ($8.9) billion in aggregate and $8,748 ($9,896) per pt (BMUS 4th ed.30†) - $596 ($704) per pt incremental; $252 ($298) million national cost due to RA-related absenteeism (Gunnarsson et al40**) - $3,324 ($3,573) RA-related per pt on targeted immunomodulators (Strand et al42) |
- $46 ($52) billion national all-cause; $21.6 ($24.4) billion RA-related costs (BMUS 4th ed.30†) - $8,641 ($9,593) per pt for RA-related, targeted immunomodulators (Strand et al42) |
- 236% higher relative prevalence of functional disability compared to age-matched controls (Myasoedova et al41) | - 20.3 days of work lost per yr for pts on targeted immunomodulators (Strand et al42) - 13.7 workdays missed per yr (about 4 days more than those without condition) (Gunnarsson et al40) |
Spinal Cord Injury | - 2.6 million (James et al61†) - 291,000 (National Spinal Cord Injury Statistical Center60†) - 1.5 million (Armour et al62†) |
- 52–54 per 1,000,000 traumatic (Jain et al63**, National Spinal Cord Injury Center60†) - 56.4 per 1,000,000 traumatic (Selvarajah et al65**) - 260 per 1000,000 (James et al61†) |
Overall: - $1.7 ($2.2) billion cost of hospital izations (Mahabaleshwarkar and Khanna66**) - $1.6 ($2.1) billion acute treatment (Selvarajah et al65*) - $42,323 ($50,280) and $35,883 ($42,629) all-cause costs for patients with and without neuropathic pain, respectively (Margolis et al121) Cervical: - $1,129,302 ($1,148,407) in first yr then $196,107 (199,425) per yr after in SCI-related costs (DeVivo et al;68 National Spinal Cord Injury Center60†) -$160,000-$180,000 ($166,000–187000) in hospitalization costs per pt ≥65 (Asemota et al122) |
- $76,327 ($77,334) per person (National Spinal Cord Injury Center, 201960†) | - $9.7 ($15.7) billion (Berkowitz et al69 p. 81; Ma et al5) |
Overall: - Average spasticity was mild and persists in roughly 85% of pts (DiPiro et al71) Cervical: - Of those with CSCI, roughly 60% incomplete tetraplegia vs 40% complete tetraplegia. Of all DALYs associated with SCI, cervical SCIs account for roughly 66% (Hall et al67) |
- 35% employed after SCI (Trenaman et al;72 Ottomanelli et al73) |
Stroke | - 2.5% or 7.0 million adults ≥20 yrs (Benjamin et al74†) - 2.9–3.7% of adults (Blackwell and Villarroel;76†CDC106†) - 2.6% among all ages; peak prevalence is 17.3% among adults aged 90–94 (IHME GBD Tool 201732†) |
- 192 per 100,000 men; 198 per 100,000 women (Madsen et al79**) - 127 per 100,000 acute ischemic stroke (Alqahtani et al123) - 373 per 100,000 for total stroke; 329 per 100,000 for ischemic; 49 per 100,000 for hemorrhagic stroke (Koton et al124) - 639 per 100,000 first stroke in pts ≥65 years old (Fang 2014125) - 795,000 cases of new/recurrent stroke based on 1999 data (Benjamin et al74†) - 185 per 100,000 incidence among all ages; peak incidence is 2,085 per 100,000 among adults aged 90–94 (IHME GBD Tool 201732†) |
- $21,916 ($32103) mean hospital charges for acute ischemic stroke in 2016 (Yacoub et al82**) - $28 ($30.9) billion (Benjamin et al74†) - $2.34 ($2.78) billion national hospitalization costs due to subarachnoid hemorrhage, $2.52 ($2.99) billion due to ischemic hemorrhage, and $12.55 ($14.9) billion due to acute ischemic stroke (Tong etal83*) - $18,796 ($22,330) per pt all-cause medical costs (Chinthammit et al89**) - $24 ($25.5) billion incremental among patients with hypertension who have stroke (Lekoubou et al80*) - $46,518 ($61,046) per admission (Stepanova et al81*) - $46,850 ($51,684) all-cause medical costs in first year post-injury (Mu et al87) - All-cause costs were $61,354 ($71,139) per pt on commercial health insurance vs $44,929 ($52,095) per pt on Medicare in first year (Johnson et al;126 Katan and Luft127) - $20,396 ($27,611) per admission for primary and secondary diagnosis of stroke (Wang et al128) |
- $30 ($31.1) billion stroke-related lost productivity (RTI International129) - $33.65 ($39.25) billion lost productivity (Ovbiagele et al84**) - $8,211 ($9,703) per pt annual cost due to informal caregiving (Joo et al85*) |
- $45.5 ($48.8) billion stroke-related (Benjamin et al74†) | - 3% of males and 2% of females attribute disability to stroke (Benjamin et al74†) - 60% reported at least some difficulty (w/ or w/o assistive device) in completing ADLs (≥65 years old) (Brenner et al90) - Majority reported severe to extreme difficulty with standing for long periods and walking a long distance (64.5%). Pts were restricted in self-care activities including bathing (40.8%) and performing household tasks (40.2%) (older Americans, most commonly 60–69 yrs old) (Arowoiya et al91) - 22% were discharged with disability (mean age of 64 years old) (Mu et al87) - Significantly higher percentage of patients with stroke (>65 yrs) report balance/coordination problems (52.4%) and use of a mobility device (22.8%) compared to controls without stroke (Wing etal92) - 23.1% reported ADL limitation (>50 yrs) (Chinthammit et al89) - 65–121% more likely to require help in self-care, mobility, and household activities than matched controls (≥65 years old) (Skolarus et al88) |
- 45.6% of participants with stroke in a community stated that they were unemployed as a result of their stroke (60–69 yrs) (Arowoiya et al91) |
TBI | - Age-standardized rate of 605 per 100,000 (James et al61†) - 21.7% of state-based population report at least 1 TBI with LOC in lifetime (Corrigan et al130) - 42.5% of state-based population report lifetime history of TBI, the most common of which was mild TBI (Whiteneck et al102) |
- 2.8 million annual TBI-related emergency department visits, hospitalizations, and deaths among all ages (Taylor et at al93**) - 807.9 mild TBI per 100,000 ED visits (Cancelliere et al98**) - 1.6% of all injury- or illness-related ED visits in one state contained diagnosis code for TBI (Kerr et al131) - 2.9 million TBI-related ED visits, hosp., deaths among all ages (CDC94†) - Age-standardized rate of 333 per 100,000 (James et al61†) |
- $21.4 ($27.2) billion TBI-related admissions and $8.2 ($10.4) billion discharges/transports (Marin et al99*) - $9.2 ($17.4) billion injury-related (Finkelstein et al100 p. 68; Ma et al5) |
- $51.2 ($75.6) billion (Finkelstein et al100 p. 104; Ma et al5) | - $60.4 ($93.0) billion in lifetime costs (Finkelstein et al100 p. 136; Ma et al5) | - Roughly 50% do not return to pre-injury level in 1 year (Nelson et al101) - Based on state data, 41% of hospitalized pts with TBI and 33% of non-hospitalized pts with TBI report activity limitations. Prevalence of activity limitations increased by up to 307% compared to healthy controls without TBI, in accordance with injury severity (Whiteneck et al102) - Of those with moderate to severe TBI at 1 year post-injury, FIM scores were lowest in the domains of stair climbing, memory, and problem solving (Brooks et al132) |
- More than half of moderate/severe TBI were unemployed at 2 and 5 years post-injury (Cuthbert et al;103DiSanto et al104) - Roughly 80% of veterans with severe TBI were unemployed 1 year post-injury (Dillahunt-Aspillaga et al105) |
fair quality;
good quality OR no major flaws;
grey literature
Abbreviations:ADL – activities of daily living; cLBP – chronic low back pain; CSCI – cervical spinal cord injury; DALY – disability-adjusted life year; DMD – disease modifying drug; ED – emergency department; LBP – low back pain; LEA – lower extremity amputation; LOC – loss of consciousness; MS – multiple sclerosis; OA – osteoarthritis; PT – patient; RA – rheumatoid arthritis; SCI – spinal cord injury; TBI – traumatic brain injury; YR – year